Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 5/20 | 0.41 |
| ▸ | RXRG | P48443 | 5/20 | 0.41 |
| ▸ | RXRB | P28702 | 4/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 2/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602132 | 0.93 | RXRA (0.44) | RXRARXRGRXRBPTGDR2 | |
| SCHEMBL3593876 | 0.93 | RXRA (0.52) | RXRARXRGRXRBPTGDR2XDH | |
| SCHEMBL3593291 | 0.92 | RXRA (0.38) | RXRARXRGRXRBPTGDR2XDH | |
| SCHEMBL3605853 | 0.92 | RXRA (0.38) | RXRARXRGRXRBPTGDR2 | |
| SCHEMBL3596946 | 0.89 | RXRA (0.46) | RXRARXRGRXRBPTGDR2 | |
| SCHEMBL3604529 | 0.88 | XDH (0.48) | PTGDR2XDH | |
| SCHEMBL4386221 | 0.88 | PTGDR2 (0.39) | RXRARXRGRXRBPTGDR2AKR1C3 | |
| SCHEMBL3596237 | 0.88 | PTGDR2 (0.39) | RXRARXRGPTGDR2XDH | |
| SCHEMBL4139396 | 0.88 | RXRA (0.35) | RXRARXRGRXRBPTGDR2XDH | |
| SCHEMBL3603924 | 0.87 | XDH (0.44) | RXRARXRGRXRBPTGDR2XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2010-04-08 | — | — | US | claimed |
| EP-1828172-B1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-11-25 | — | — | EP | claimed |
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2010-04-08 | — | — | US | disclosed |
| EP-1828172-B1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | PRLHR, AVPR2, CRHR2 | RXRA 426/4885RXRG 377/4885RXRB 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.